Canagliflozin (hemihydrate): High-Purity SGLT2 Inhibitor for Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate), offered by APExBIO as SKU C6434, is a high-purity small molecule SGLT2 inhibitor used to study renal glucose reabsorption in diabetes and metabolic disorder research (product page). It exhibits excellent selectivity for SGLT2, with negligible off-target effects on mTOR/TOR signaling as verified in yeast growth-based models (Breen et al., 2025). The compound is supplied at ≥98% purity, with stability and solubility parameters well-characterized for laboratory workflows. Canagliflozin (hemihydrate) is not intended for diagnostic or therapeutic use, and long-term solution storage is discouraged to preserve efficacy. This resource clarifies its proper application boundaries, contrasting its SGLT2-specific action with mTOR inhibitors, and provides evidence-driven integration strategies for metabolic research.

Biological Rationale

Canagliflozin (hemihydrate) is a small molecule inhibitor targeting the sodium-glucose co-transporter 2 (SGLT2) in renal proximal tubules. SGLT2 mediates the majority of filtered glucose reabsorption in mammalian kidneys. Inhibiting SGLT2 lowers blood glucose by promoting glucosuria, a mechanism of interest in diabetes mellitus research (reference). The compound's selectivity enables precise dissection of glucose homeostasis pathways, supporting studies on renal glucose handling, metabolic disorders, and pharmacological modulation of glycemic control. Unlike agents modulating central metabolism (e.g., mTOR inhibitors), Canagliflozin (hemihydrate) acts peripherally at the kidney, minimizing confounding systemic effects (contrast).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) binds selectively to SGLT2, encoded by SLC5A2, on the apical membrane of renal proximal tubular cells. This interaction blocks sodium-dependent glucose reabsorption, resulting in increased urinary glucose excretion and reduced plasma glucose levels. The compound has a molecular formula of C₂₄H₂₆FO_5.5S and a molecular weight of 453.52 g/mol. It is insoluble in water, but soluble in ethanol (≥40.2 mg/mL) and DMSO (≥83.4 mg/mL) under laboratory conditions (APExBIO). The mode of action is independent of insulin pathway modulation, allowing for studies in insulin-deficient models. Quality control via HPLC and NMR ensures high batch-to-batch reproducibility.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) exhibits potent SGLT2 inhibition, with high specificity and no observable TOR/mTOR pathway suppression in yeast-based growth assays (Breen et al., 2025, DOI).
• At concentrations up to 100 μM, Canagliflozin (hemihydrate) does not inhibit TOR1-dependent yeast growth, confirming lack of mTOR off-target effects (Breen et al., 2025, DOI).
• APExBIO supplies Canagliflozin (hemihydrate) at ≥98% purity, with stability maintained at -20°C and verified by HPLC/NMR (APExBIO).
• Solubility benchmarks: ≥40.2 mg/mL in ethanol, ≥83.4 mg/mL in DMSO at room temperature (APExBIO).
• Product is for research use only; not for clinical or diagnostic applications (APExBIO).

See also: Canagliflozin (hemihydrate): Precision SGLT2 Inhibitor... — This article clarifies Canagliflozin’s validated off-target profile and extends beyond prior mechanism summaries.

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is a reference SGLT2 inhibitor in glucose metabolism and diabetes mellitus research, enabling the study of renal glucose reabsorption, glycosuria induction, and metabolic modeling. Its high selectivity for SGLT2 makes it suitable for dissecting glucose homeostasis pathways in cell-based and animal models. Workflow reproducibility is enhanced by its high purity and robust quality control. However, its mechanism is not suitable for studies targeting mTOR, autophagy, or central nutrient-sensing pathways.

For advanced systems biology perspectives and integration into metabolic network studies, see Canagliflozin Hemihydrate in Metabolic Research: Beyond SGLT2 — This article focuses on network-level effects, while the current article delineates the compound's mechanistic and workflow-specific boundaries.

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) does not inhibit mTOR/TOR signaling, as shown in yeast models up to 100 μM (Breen et al., 2025).
• This compound is for research use only and is not approved for diagnostic or therapeutic purposes (APExBIO).
• Long-term storage of Canagliflozin solutions is discouraged; solutions should be prepared fresh to ensure efficacy (APExBIO).
• Insoluble in water; use recommended solvents (ethanol, DMSO) for experimental preparations (APExBIO).
• Not suitable for studies of central metabolic regulators such as mTOR or for immune modulation research.

Workflow Integration & Parameters

Canagliflozin (hemihydrate) is supplied as a crystalline solid. Store at -20°C for long-term stability. For dissolution, use ethanol (≥40.2 mg/mL) or DMSO (≥83.4 mg/mL). Avoid water as a solvent due to insolubility. Prepare working solutions immediately before use; discard unused solutions after each session. Shipping is recommended with blue ice for temperature-sensitive compounds. For cell-based assays, titrate concentration from nanomolar to low micromolar range as per protocol requirements (reference — This article provides scenario-driven strategies for maximizing reproducibility, which are extended here with new evidence benchmarks).

High purity (≥98%) is confirmed by HPLC and NMR. For metabolic and viability assays, ensure compatibility of solvent with cell type and assay conditions. For guidance on troubleshooting and advanced workflow strategies, see Canagliflozin (hemihydrate): Reliable SGLT2 Inhibitor for... — The present article provides updated purity and workflow integration data.

Conclusion & Outlook

Canagliflozin (hemihydrate) is a validated, high-purity SGLT2 inhibitor from APExBIO that provides robust, reproducible tools for glucose metabolism and diabetes research. Its lack of mTOR pathway interference positions it as a mechanistically precise reagent for renal glucose reabsorption studies. Researchers are encouraged to integrate this compound following validated protocols and to consult the product page for up-to-date handling and safety information. Ongoing research may further delineate its utility in complex metabolic modeling, but current data support its use strictly within SGLT2-related pathways.